{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:04:51Z","timestamp":1790971491716,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Korea Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2025-25460287"],"award-info":[{"award-number":["RS-2025-25460287"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-02216696"],"award-info":[{"award-number":["RS-2025-02216696"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00440273"],"award-info":[{"award-number":["RS-2024-00440273"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-00517430"],"award-info":[{"award-number":["RS-2025-00517430"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-NR077245"],"award-info":[{"award-number":["RS-2023-NR077245"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003052","name":"Ministry of Trade, Industry and Energy","doi-asserted-by":"publisher","award":["RS-2023-00217266"],"award-info":[{"award-number":["RS-2023-00217266"]}],"id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004080","name":"Korea Drug Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004080","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","award":["IBS-R008-D1"],"award-info":[{"award-number":["IBS-R008-D1"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Biotechnology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.tibtech.2026.08.008","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:00:40Z","timestamp":1788793240000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A logic-gated synthetic circuit coupled with microenvironmental reprogramming overcomes immune exclusion in antigen-poor chondrosarcoma"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4742-863X","authenticated-orcid":false,"given":"Jooyeon","family":"Suh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7676-6917","authenticated-orcid":false,"given":"Geunho","family":"Yook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3788-8880","authenticated-orcid":false,"given":"Junhan","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8758-9628","authenticated-orcid":false,"given":"Sehan","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5703-6678","authenticated-orcid":false,"given":"Somin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8899-5342","authenticated-orcid":false,"given":"June Hyuk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1994-6990","authenticated-orcid":false,"given":"Hyun Guy","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2533-8484","authenticated-orcid":false,"given":"Ming-Ru","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1763-4267","authenticated-orcid":false,"given":"Yi-Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6480-1929","authenticated-orcid":false,"given":"Jin-Hong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tibtech.2026.08.008_bb0005","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.tibtech.2026.08.008_bb0010","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways","volume":"19","author":"Kraehenbuehl","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0020","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s43018-021-00241-5","article-title":"Engineering enhanced CAR T-cells for improved cancer therapy","volume":"2","author":"Milone","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.tibtech.2026.08.008_bb0025","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0030","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.tibtech.2026.08.008_bb0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41392-019-0070-9","article-title":"Genetically engineered T cells for cancer immunotherapy","volume":"4","author":"Li","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0040","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41587-024-02446-2","article-title":"Beyond the blood: expanding CAR T cell therapy to solid tumors","volume":"43","author":"Uslu","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0045","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: state of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0050","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","article-title":"CAR T cell combination therapies to treat cancer","volume":"42","author":"Uslu","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tibtech.2026.08.008_bb0055","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s41591-025-03512-1","article-title":"Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma","volume":"31","author":"Long","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0060","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S1470-2045(25)00429-2","article-title":"Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis","volume":"26","author":"Di Federico","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0065","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41591-025-03532-x","article-title":"An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma","volume":"31","author":"Raj","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0070","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1038\/s41591-022-02154-x","volume":"28","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0075","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D\u2019Angelo","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.tibtech.2026.08.008_bb0080","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1038\/s41591-025-03650-6","article-title":"Autologous T cell therapy for PRAME(+) advanced solid tumors in HLA-A*02(+) patients: a phase 1 trial","volume":"31","author":"Wermke","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0085","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41586-025-09507-9","article-title":"Systematic discovery of CRISPR-boosted CAR T cell immunotherapies","volume":"646","author":"Datlinger","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.tibtech.2026.08.008_bb0090","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ado9371","article-title":"CAR T cells based on fully human T cell receptor-mimetic antibodies exhibit potent antitumor activity in vivo","volume":"17","author":"Salzler","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0095","doi-asserted-by":"crossref","first-page":"579","DOI":"10.14348\/molcells.2023.0079","article-title":"Sarcoma immunotherapy: confronting present hurdles and unveiling upcoming opportunities","volume":"46","author":"Jeong","year":"2023","journal-title":"Mol Cells"},{"key":"10.1016\/j.tibtech.2026.08.008_bb0100","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/modpathol.2016.108","article-title":"Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype","volume":"29","author":"Kostine","year":"2016","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0105","article-title":"The immune landscape of chondrosarcoma reveals an immunosuppressive environment in the dedifferentiated subtypes and exposes CSFR1+ macrophages as a promising therapeutic target","volume":"20","author":"Iseulys","year":"2020","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0110","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1265716","article-title":"Description of the immune microenvironment of chondrosarcoma and contribution to progression","volume":"6","author":"Simard","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.tibtech.2026.08.008_bb0115","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231199877","article-title":"Role of immunotherapy in chondrosarcoma: a case report and review of the literature","volume":"15","author":"Cohen-nowak","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0120","first-page":"199","article-title":"Emerging mechanisms of immunotherapy resistance in sarcomas","volume":"5","author":"Florou","year":"2022","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0125","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0130","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D\u2019Angelo","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0135","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.7150\/jca.30388","article-title":"Predictors of the survival of patients with chondrosarcoma of bone and metastatic disease at diagnosis","volume":"10","author":"Wang","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.tibtech.2026.08.008_bb0140","doi-asserted-by":"crossref","first-page":"440","DOI":"10.52312\/jdrs.2022.526","article-title":"Evaluation of prognostic factors affecting survival in chondrosarcoma treatment and comparison with literature","volume":"33","author":"Coskun","year":"2022","journal-title":"Jt Dis. Relat. Surg."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0145","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.cell.2017.09.049","article-title":"Synthetic RNA-based immunomodulatory gene circuits for cancer immunotherapy","volume":"171","author":"Nissim","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.tibtech.2026.08.008_bb0150","doi-asserted-by":"crossref","first-page":"7983","DOI":"10.1038\/s41467-025-63377-3","article-title":"Reprogramming the tumor microenvironment with c-MYC-based gene circuit platform to enhance specific cancer immunotherapy","volume":"16","author":"Zhan","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0155","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1038\/s41467-019-10912-8","article-title":"A high-throughput screening and computation platform for identifying synthetic promoters with enhanced cell-state specificity (SPECS)","volume":"10","author":"Wu","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0160","article-title":"TREND: A generalizable synthetic enhancer discovery platform for targeted immunotherapy","author":"Jia","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.tibtech.2026.08.008_bb0165","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1021\/sb200015u","article-title":"SYNZIP protein interaction toolbox: in vitro and in vivo specifications of heterospecific coiled-coil interaction domains","volume":"1","author":"Thompson","year":"2012","journal-title":"ACS Synth. Biol."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0170","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s42003-024-05790-w","article-title":"A single-cell atlas of conventional central chondrosarcoma reveals the role of endoplasmic reticulum stress in malignant transformation","volume":"7","author":"Su","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0175","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1038\/s41467-019-12525-7","article-title":"Integrated molecular characterization of chondrosarcoma reveals critical determinants of disease progression","volume":"10","author":"Nicolle","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.609948","article-title":"MIF-dependent control of tumor immunity","volume":"11","author":"Noe","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0185","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-023-02371-y","article-title":"Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance","volume":"29","author":"Chu","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0190","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ccell.2025.01.007","article-title":"Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer","volume":"43","author":"Zhang","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tibtech.2026.08.008_bb0195","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc7804","article-title":"Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models","volume":"13","author":"Hotz","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0200","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54877-9","article-title":"Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity","volume":"15","author":"Hamouda","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0205","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrg3742","article-title":"Engineering adeno-associated viruses for clinical gene therapy","volume":"15","author":"Kotterman","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0210","doi-asserted-by":"crossref","DOI":"10.1002\/adma.70627","article-title":"Engineering CRISPR system-based bacterial outer membrane vesicle potentiates T cell immunity for enhanced cancer immunotherapy","volume":"37","author":"Wang","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0215","doi-asserted-by":"crossref","first-page":"D816","DOI":"10.1093\/nar\/gkn673","article-title":"CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens","volume":"37","author":"Almeida","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0220","doi-asserted-by":"crossref","DOI":"10.1093\/database\/bau012","article-title":"COMPARTMENTS: unification and visualization of protein subcellular localization evidence","volume":"2014","author":"Binder","year":"2014","journal-title":"Database (Oxford)"},{"key":"10.1016\/j.tibtech.2026.08.008_bb0225","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/pro.3307","article-title":"The human protein atlas: a spatial map of the human proteome","volume":"27","author":"Thul","year":"2018","journal-title":"Protein Sci."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0230","doi-asserted-by":"crossref","first-page":"D1210","DOI":"10.1093\/nar\/gkad986","article-title":"COSMIC: a curated database of somatic variants and clinical data for cancer","volume":"52","author":"Sondka","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tibtech.2026.08.008_bb0235","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","article-title":"Conserved pan-cancer microenvironment subtypes predict response to immunotherapy","volume":"39","author":"Bagaev","year":"2021","journal-title":"Cancer Cell"}],"container-title":["Trends in Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167779926003434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167779926003434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:07:00Z","timestamp":1788898020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167779926003434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":47,"alternative-id":["S0167779926003434"],"URL":"https:\/\/doi.org\/10.1016\/j.tibtech.2026.08.008","relation":{},"ISSN":["0167-7799"],"issn-type":[{"value":"0167-7799","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A logic-gated synthetic circuit coupled with microenvironmental reprogramming overcomes immune exclusion in antigen-poor chondrosarcoma","name":"articletitle","label":"Article Title"},{"value":"Trends in Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tibtech.2026.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}